Onkologie. 2008:2(3):174-178

CANCER ANOREXIA/CACHEXIA SYNDROME

Miroslav Tomíška
Interní hematoonkologická klinika LF MU a FN Brno

Cancer cachexia is a syndrome of progressive weight loss which causes significant morbidity and mortality in cancer patients. Metabolic derangements conditioned by proinflammatory cytokines, ultimately leading to muscle and fat depletion, are frequently operating early after tumor onset so cancer cachexia has to be viewed as an early phenomenon. The presence of acute phase response accounts for limited effectiveness of nutritional therapy alone especially in advanced malnutrition. However, cancer cachexia in early stages is at least partially preventable.

The easiest way of nutrition support is an early and systematic use of high-protein oral nutritional supplements to prevent further weight loss. For more severe cases, multimodal treatment containing nutritional therapy, pharmacological amelioration of acute phase response and anabolic support by physical activity and/or anabolic steroids will be necessary in the near future. The use of n-3 polyunsaturated fatty acids contained in fish oil may contribute to lower the loss of weight, maintain of lean body mass and improve quality of life.

Keywords: Key words: cancer cachexia, anorexia, nutrition support.

Published: November 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tomíška M. CANCER ANOREXIA/CACHEXIA SYNDROME. Onkologie. 2008;2(3):174-178.
Download citation

References

  1. Tisdale MJ. Cachexia in cancer patients. Nature Reviews 2002; 2: 862-871. Go to original source... Go to PubMed...
  2. Barber MD, Ross JA, Fearon KCH. Cancer cachexia. Surg Oncol 1999; 8: 133-141. Go to original source... Go to PubMed...
  3. Kotler DP. Cachexia. Ann Int Med 2000; 133: 622-634. Go to original source... Go to PubMed...
  4. Kim HL, Han KR, Zisman A. Figlin RABelldegrun AS. J Urol 2004; 171: 1810-1813. Go to original source... Go to PubMed...
  5. Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr 2005; 8: 265-269. Go to original source... Go to PubMed...
  6. Ramos EJB, Suzuki S, Marks D, Inui A, Asakawa A, Meguid MM. Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. Curr Opin Clin Nutr 2004; 7: 427-434. Go to original source... Go to PubMed...
  7. Muscaritoli M, Bossola M, Bellantone R, Fanelli FR. Therapy of muscle waisting in cancer: what is the future? Curr Opin Clin Nutr 2004; 7: 459-466. Go to original source... Go to PubMed...
  8. Tisdale MJ. The, cancer cachectic factor'. Support Care Cancer 2003; 11: 73-78. Go to original source... Go to PubMed...
  9. Skipworth RJE, Stewart GD, Dejong CHC, Preston T, Fearon KCH. Pathophysiology of cancer cachexia: Much more than host-tumor interaction? Clin Nutr 2007; 26: 667-676. Go to original source... Go to PubMed...
  10. Grimble RF. Nutritional therapy for cancer cachexia. Gut 2003; 52: 1391-1392. Go to original source... Go to PubMed...
  11. Fearon KCH. The anticancer and anticachectic effects of n-3 fatty acids. Clin Nutr 2002; 21 Suppl 2: 73-77.
  12. Jatoi A, Rowland K, Loprinzi ChL. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada Collaborative Effort. J Clin Oncol 2004; 22: 2469-2476. Go to original source... Go to PubMed...
  13. Fearon KCH, Barber MD, Moses AG et al. Double-blind, placebo controlled, randomised study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 2006; 24: 3401-3407. Go to original source... Go to PubMed...
  14. Moses AWG, Slater C, Preston T et al. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 2004; 90: 996-1002. Go to original source... Go to PubMed...
  15. Fearon KCH, Meyenfeldt MF, Moses AWG et al. Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 2003; 52: 1479-1486. Go to original source... Go to PubMed...
  16. Mateen F, Jatoi A. Magestrol acetate for the palliation of anorexia in advanced, incurable cancer patients. Clin Nutr 2006; 25: 711-715. Go to original source... Go to PubMed...
  17. Strasser F, Luftner D, Possinger K et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter phase III, randomised, double-blind, placebo-controlled clinical trial from the Cannabis-In-CachexiaStudy-Group. J Clin Oncol 2006; 24: 3394-3400. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.